Rossouw, J., Anderson, G., Prentice, R., LaCroix, A., Kooperberg, C., Stefanick, M., Jackson, R., Beresford, S., Howard, B., Johnson, K., Kotchen, J. and Ockene, J. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health initiative randomized controlled trial. Journal American Medical Association, 288, 321-333. doi:10.1001/jama.288.3.321

has been cited by the following article:

• TITLE: Relief of hot flashes with escitalopram in non-depressed menopausal women in Japan: Results of a retrospective analysis

  AUTHORS: Chikako Mori, Atsushi Imai

  KEYWORDS: Hot Flashes; Escitalopram; Selective Serotonin Reuptake Inhibitors; Menopause

  JOURNAL NAME: Health, Vol.4 No.10, November 1, 2012

  ABSTRACT: Purpose: Hormone therapy (estrogen with or without progestin) remains the gold standard treatment for hot flashes in menopausal women, but concerns for the risk of hormone therapy have resulted in its decline and a demand for nonhormonal treatments with demonstrated efficacy for hot flashes. Aim of this study was to examine the efficacy of selective serotonin reuptake inhibitor escitalopram on hot flashes in a healthy sample of non-depressant menopausal women in Japan. Methods: We retrospectively analyzed the medical records of 11 menopausal patients with hot flashes, who received escitalopram (10 mg daily) for 2 weeks between March and August 2012. Hot flashes severities and scores were recorded on a scale of 0 to 10 points, at beginning and end of 2 weeks treatment. Results: At 2 weeks of therapy, 9 of 11 patients reported significant decreases in hot flash frequency and severity, but the remission of the symptom was not observed in 2 patients. Speed of relief from hot flashes was rapid (within one week). Conclusions: Escitalopram 10 mg/day may be a prompt and effective option for treating hot flashes in menopausal women who do not want to use hormone replacement therapy.